{"id":296220,"date":"2026-09-01T00:00:00","date_gmt":"2026-09-01T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0040-2024-biopharma-rheumatoid-arthritis-current-treatment-treatment-algorithms-claims-data\/"},"modified":"2026-09-24T11:17:20","modified_gmt":"2026-09-24T11:17:20","slug":"algoim0040-2026-biopharma-rheumatoid-arthritis-current-treatment-treatment-algorithms-claims-data-analysis-rheumatoid","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0040-2026-biopharma-rheumatoid-arthritis-current-treatment-treatment-algorithms-claims-data-analysis-rheumatoid\/","title":{"rendered":"Rheumatoid Arthritis &#8211; Current Treatment &#8211; Treatment Algorithms: Claims Data Analysis &#8211; Rheumatoid Arthritis (US)"},"content":{"rendered":"<p>The treatment of rheumatoid arthritis (<abbr title=\"rheumatoid arthritis\">RA<\/abbr>) typically begins with cost-effective conventional <abbr title=\"disease-modifying antirheumatic drug\">DMARD<\/abbr>s (<abbr title=\"conventional disease-modifying antirheumatic drug\">cDMARD<\/abbr>s) such as methotrexate or hydroxychloroquine. For patients who fail <abbr title=\"conventional disease-modifying antirheumatic drug\">cDMARD<\/abbr> treatment or have an inadequate response, the U.S. market is offers an array of efficacious biologics and targeted oral therapies, including leading<abbr title=\"tumor necrosis factor\">TNF<\/abbr>-alpha inhibitors (e.g., AbbVie\u2019s Humira, Amgen\u2019s Enbrel) and non-<abbr title=\"tumor necrosis factor\">TNF<\/abbr>-alpha inhibitors, such as Bristol Myers Squibb\u2019s Orencia and Roche\u2019s Actemra and the oral <abbr title=\"Janus kinase\">JAK<\/abbr> inhibitors Xeljanz (Pfizer), Olumiant (Eli Lilly), and Rinvoq (AbbVie). The approval of Rinvoq has increased the competition in the <abbr title=\"Janus kinase\">JAK<\/abbr> inhibitor class and among the non-<abbr title=\"tumor necrosis factor\">TNF<\/abbr> biologics. However, the <abbr title=\"Food and Drug Administration\">FDA<\/abbr>\u2019s safety warnings regarding the <abbr title=\"Janus kinase\">JAK<\/abbr> inhibitor class may influence prescribing behavior, leading to greater uptake of other targeted agents.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What patient shares do key therapies and brands garner by line of therapy in newly diagnosed <abbr title=\"rheumatoid arthritis\">RA<\/abbr> patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed <abbr title=\"rheumatoid arthritis\">RA<\/abbr> patients?<\/li>\n<li>How have <abbr title=\"Janus kinase\">JAK<\/abbr> inhibitors been integrated into the treatment algorithm, and what are their sources of business?<\/li>\n<li>What percentage of <abbr title=\"rheumatoid arthritis\">RA<\/abbr> patients receive drug therapy within three years of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within three years of diagnosis?<\/li>\n<li>What percentage of <abbr title=\"rheumatoid arthritis\">RA<\/abbr> patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients?<\/li>\n<\/ul>\n<p><strong>Geography:<\/strong> United States<\/p>\n<p><strong>Real-world data: <\/strong>U.S. pharmacy and medical claims data<\/p>\n<p><strong>Key drugs:<\/strong> Enbrel, Humira, Remicade, Orencia, Actemra, Olumiant, Kevzara, Rituxan, Xeljanz, Rinvoq, Cimzia<\/p>\n<p><strong>Key analyses<\/strong>: Brand \/ therapy usage across longitudinal patient sample, newly diagnosed patient analysis, treatment initiation and progression, line of therapy analysis, combination therapy analysis, source of business for recently treated patients, persistency and compliance analysis, product-level patient flow<\/p>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Understand patient flow between lines of therapy.<\/li>\n<li>Evaluate your brand share against competitors.<\/li>\n<li>Accurately assess your source of business.<\/li>\n<li>Quantify opportunities at different stages of the treatment algorithm.<\/li>\n<\/ul>\n<p><strong>PRODUCT ENHANCEMENT<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis leverages Clarivate\u2019s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.<\/p>\n","protected":false},"template":"","class_list":["post-296220","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-rheumatoid-arthritis","biopharma-therapy-areas-rheumatology","biopharma-product-current-treatment","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296220","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=296220"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}